Exicure, Inc. (NASDAQ:XCUR) Sees Significant Increase in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 55,900 shares, an increase of 71.5% from the September 15th total of 32,600 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 8.5% of the company’s stock are sold short.

Exicure Price Performance

Exicure stock opened at $2.68 on Friday. Exicure has a one year low of $1.44 and a one year high of $6.00. The company’s fifty day moving average price is $1.81 and its two-hundred day moving average price is $0.93. The company has a market capitalization of $4.64 million, a price-to-earnings ratio of -0.59 and a beta of 1.28.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insider Activity

In other news, major shareholder Co. Ltd. Dgp acquired 237,223 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $3.00 per share, for a total transaction of $711,669.00. Following the completion of the acquisition, the insider now owns 849,223 shares of the company’s stock, valued at approximately $2,547,669. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is owned by corporate insiders.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.